期刊
ACS OMEGA
卷 4, 期 1, 页码 1157-1166出版社
AMER CHEMICAL SOC
DOI: 10.1021/acsomega.8b02781
关键词
-
资金
- National Institutes of Health (NIH) [R15GM114701]
Osteoporosis is a common metabolic bone disorder associated with fragility and bone fracture. Worldwide, osteoporosis results in more than 8.9 million fractures annually. Additionally, steroid treatments can cause osteoporosis as a side effect. Salmon calcitonin (sCT) is injected daily for those on steroid treatments as a means to prevent and treat osteoporosis side effects. Frequent dosing is inconvenient, uncomfortable, and often leads to compliance issues. Our objective was to develop a monomethoxy poly(ethylene glycol) (mPEG) and poly-lactic-co-glycolic acid (PLGA) thermosensitive triblock copolymer (mPEG-PLGA-mPEG)-based controlled release delivery system at an increased lactide to glycolide ratio (3.5:1, 4.5:1, and 5:1) to deliver sCT in its active conformation in a controlled fashion for a prolonged period following a single subcutaneous injection. Increasing lactide to glycolide ratio increases hydrophobicity of the PLGA block, which slows degradation of copolymer, thereby prolonging release and reducing burst release. Proton nuclear magnetic resonance spectroscopy and gel permeation chromatography confirmed structural composition and polydispersity index, respectively. Critical micelle concentration of the copolymer was 25 mu g/mL. The delivery system was biocompatible as determined using 3-(4,5-dimethylthiazol- 2-yl)-2,5-diphenyltetrazolium bromide cell viability assay. Moreover, the copolymeric system maintained sCT in a conformationally stable form for the entire duration of storage and release.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据